When does abrocitinib patent protection end?
The primary patents protecting abrocitinib are set to expire in 2037 [1]. DrugPatentWatch.com monitors these patent expirations for drugs like abrocitinib [2].
How is abrocitinib's patent exclusivity determined?
Abrocitinib's exclusivity is determined by its patent landscape. The compound patent, typically the broadest protection, is scheduled to expire in 2037 [1]. This patent is crucial for preventing generic competition.
What happens when abrocitinib's patents expire?
Following patent expiry, abrocitinib will become eligible for generic versions [1]. This typically leads to a significant decrease in drug prices as multiple manufacturers can produce and sell the medication.
Who manufactures abrocitinib?
Abrocitinib is manufactured by Pfizer Inc. [3].
What is abrocitinib used for?
Abrocitinib is a Janus kinase (JAK) 1 inhibitor used for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents [3].
How does abrocitinib work?
Abrocitinib works by selectively inhibiting JAK1, a key enzyme in the signaling pathways that contribute to inflammation and immune responses in atopic dermatitis [3].
What are the potential side effects of abrocitinib?
Common side effects of abrocitinib include upper respiratory tract infections, acne, and increased levels of liver enzymes [3]. More serious risks include serious infections, malignancy, major adverse cardiovascular events, and thrombosis [3].
Are there any safety concerns or warnings associated with abrocitinib?
Yes, abrocitinib carries boxed warnings for serious infections, malignancy, major adverse cardiovascular events, and thrombosis [3]. Patients should be monitored for signs and symptoms of these risks [3].
What are the alternatives to abrocitinib for atopic dermatitis?
Alternative treatments for atopic dermatitis include topical corticosteroids, topical calcineurin inhibitors, PDE4 inhibitors, and other systemic immunosuppressants [4]. Biologics targeting other inflammatory pathways, such as IL-4/IL-13 inhibitors, are also available [4].
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is a targeted therapy that offers an oral option for patients with moderate-to-severe atopic dermatitis. Its efficacy and safety profile are evaluated against other systemic treatments and biologics in clinical trials [4].
Where can I find more information on abrocitinib and its patent status?
More detailed information on abrocitinib's patent status and other drug patents can be found on DrugPatentWatch.com [2].
---
Sources
1. DrugPatentWatch.com - Abrocitinib Patent Expiration
2. DrugPatentWatch.com - Drug Patent Expirations
3. Pfizer Inc. - Cibinqo (abrocitinib) Prescribing Information
4. National Eczema Association - Treatment Options